CAR-NK在实体瘤治疗中的研究进展  

Research advances of CAR-NK cell therapy in solid tumors

作　　者：严吉 尹刚 邓国英[1] YAN Ji;YIN Gang;DENG Guoying(Shanghai First People's Hospital,Shanghai 201620,China;Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China.)

机构地区：[1]上海市第一人民医院,上海201620 [2]上海交通大学医学院,上海200025

出　　处：《现代肿瘤医学》2023年第5期964-968,共5页Journal of Modern Oncology

摘　　要：肿瘤免疫细胞治疗近年来备受瞩目。嵌合抗原受体T(chimeric antigen receptor engineered T-cell, CAR-T)细胞用于治疗血液系统恶性肿瘤已经颇见成效,但在实体瘤治疗方面却存在不足。由于具有不同于T细胞的非特异性杀伤肿瘤细胞的能力,CAR修饰的自然杀伤(nature killer, NK)细胞逐渐成为研究热点。目前,广泛的临床前研究证明了CAR-NK细胞疗法的安全性和有效性,尤其在实体瘤治疗方面,展现出了优于CAR-T细胞的应用前景。然而,CAR-NK细胞疗法仍存在一些局限性,需要进一步研究以期实现其临床转化。Tumor immune cell therapy has attracted much attention in recent years.Chimeric antigen receptor engineered T-cell(CAR-T) cells have been used to treat hematological malignancies with great success, but there are shortcomings in the treatment of solid tumors.Due to their ability to kill tumor cells differently from T cells, CAR-modified nature killer(NK) cells have gradually become a research hotspot.At present, extensive preclinical studies have proved the safety and efficacy of CAR-NK cell therapy, especially in the treatment of solid tumors, showing better application prospects than CAR-T cells.However, CAR-NK cell therapy still has some limitations, and further research is needed to achieve its clinical translation.

关 键 词：嵌合抗原受体 自然杀伤细胞 实体瘤 免疫治疗 

分 类 号：R730.5[医药卫生—肿瘤]